New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances now includes three new products including Janssen's Erleada, a next generation oral androgen receptor inhibitor for treating adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (e.g., medicine, vaccine, biologic).
You may also be interested in...
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.